Pure Global AI
NCT06364748Recruiting

Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in High-risk Patients With Cancer

West Michigan Cancer CenterClinicalTrials.govdeviceDevice trial
Study focus
Disease/Condition
Hypertension
Drug/Device/Intervention
Cellular enabled blood pressure cuff
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
West Michigan Cancer Center
Location
Kalamazoo, United States of America
Timeline & enrollment
Phase
N/A
Start date
Mar 11, 2024
End date
Sep 01, 2025
Enrollment
72 participants
Primary outcome

To determine whether remote blood pressure monitoring improves adherence to recommendations for daily systolic and diastolic blood pressure monitoring compared to usual care

Summary

A randomized trial of remote blood pressure monitoring, compared to usual care, in patients
 receiving bevacizumab to determine whether remote blood pressure monitoring improves the
 collection of blood pressure data, identification and management of clinically significant
 hypertension, and patient satisfaction.

ICD-10 classifications
Hypertensive diseasesRenovascular hypertensionSecondary hypertensionOther secondary hypertensionHypertensive heart disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06364748
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06364748 through Pure Global AI's free database. This phase not specified trial is sponsored by West Michigan Cancer Center and is currently Recruiting. The study focuses on Hypertension. Target enrollment is 72 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.